Chairman, Chief Executive Officer, founder and Chief Scientific Officer of Hua Medicine.
Dr. Chen Li is an expert and entrepreneur in new drug research and development. In 2011, He founded Hua Medicine co., LTD， and within five years, he led the global original new drug HMS5552 to successfully obtain the approval of Clinical trials in China and the United States, completed four clinical phase I and Clinical Phase II POC trials. In 2020, he successfully completed two 53-week phase III registered clinical studies, and was accepted by NMPA for NDA application in 2021.During this period, he led the company to be listed on the Hong Kong Exchanges and Clearing Limited in 2018.
He is a Ph.D. from Iowa State University, former Chief Scientific Officer of Roche China R&D Center, Chairman of US-Chinese Medicine Association, adjunct professor and doctoral supervisor of Tongji University School of Life Sciences, and part-time researcher of Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The first batch of experts selected by the National "Thousand Talents Program", Secretary-General of Shanghai New Drug Innovation Promotion Alliance, member of the American Chemical Society, and member of the American Diabetes Association.
Winners of "Top Ten Most Influential Research Awards for Diabetes in China in 2018", "2018 Commemoration of the 40 Years of Reform and Opening-up in the Pharmaceutical Industry", "2009 Shanghai Leading Talents" and other Honorary awards.
Dr. Chen is the inventor of 55 authorized invention patents and 138 invention patent applications, and has published more than 60 scientific papers.
He is currently the deputy director of the "Drug Research and Development Professional Committee" of the China Pharmaceutical Innovation Promotion Association.